(Q36772880)

16 August 2017

1 reference

title

Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease (English)

1 reference

16 August 2017

0 references

1 reference

1 reference

Rana JS

1

1 reference

16 August 2017

Nieuwdorp M

series ordinal

2

1 reference

16 August 2017

Jukema JW

series ordinal

3

1 reference

16 August 2017

Kastelein JJ

series ordinal

4

1 reference

16 August 2017

1 May 2007

1 reference

Diabetes, Obesity and Metabolism

16 August 2017

1 reference

16 August 2017

9

1 reference

16 August 2017

3

1 reference

16 August 2017

218-232

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

16 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Cardiovascular Health in Childhood: A Statement for Health Professionals From the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Diabetes trends in the U.S.: 1990-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

The metabolic syndrome: a call to action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Current concepts of the pathogenesis of the acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Inflammation: the link between insulin resistance, obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Insulin resistance, inflammation, and the prediabetic state

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

The endothelial surface layer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Oxidized lipoproteins degrade the endothelial surface layer : implications for platelet-endothelial cell adhesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

IRS proteins and the common path to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Serum leptin concentration and insulin sensitivity in men with abdominal obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Adiponectin as a biomarker of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Novel interactions of adiponectin with the endocrine system and inflammatory parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Adiponectin, the missing link in insulin resistance and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Endothelin: emerging role in diabetic vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Insulin resistance and chronic cardiovascular inflammatory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Münster.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Diabetic dyslipidaemia: from basic research to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Antiatherothrombotic effects of nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Niacin therapy in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Molecular identification of high and low affinity receptors for nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Role of CETP inhibitors in the treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

The global burden of chronic diseases: overcoming impediments to prevention and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Adiposity as Compared with Physical Activity in Predicting Mortality among Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

Diffuse and Active Inflammation Occurs in Both Vulnerable and Stable Plaques of the Entire Coronary Tree

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00594.X

10.1111/J.1463-1326.2006.00594.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference